Brexit and life sciences: uncertainty reigns but change is on the way

One potential outcome of the British vote to leave the EU is the divergence of regulatory frameworks for bringing pharmaceutical products to market in the UK and the EU—UK IP rights may split from harmonised EU systems of protection.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

Teva faces $500m fine for antitrust breaches over MS drug

Pfizer infringed haemophilia therapy patent, says court

Big Pharma counsel embrace AI but data and legal risks loom

MSN scores win in battle with Novartis over heart drug generic

HR, lobbying and business strategy…all in a day’s work for today’s counsel

Brexit and life sciences: uncertainty reigns but change is on the way

Editor's picks

Editor's picks

More features